RBC Bioscience

RBC Bioscience Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 122.73. In the previous year, Cash Conversion Cycle (CCC) was 153.91 — a change of -20.25% (lower).

Cash Conversion Cycle

122.73

YoY

-20.25%

Last updated:

Cash Conversion Cycle (CCC) of RBC Bioscience is 2024 122.73 . Cash Conversion Cycle (CCC) of RBC Bioscience was 2023 153.91 . It decreases by -20.25% lower compared to the previous year.

The RBC Bioscience Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
129.24 TWD
Jan 1, 2019
91.15 TWD
Jan 1, 2020
-20.59 TWD
Jan 1, 2021
77.91 TWD
Jan 1, 2022
142.32 TWD
Jan 1, 2023
153.91 TWD
Jan 1, 2024
122.73 TWD
The RBC Bioscience Cash Conversion Cycle history
YEARCash Conversion CycleYoY
122.73-20.25%
153.91+8.14%
142.32+82.68%
77.91-478.32%
-20.59-122.59%
91.15-29.48%
129.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Cash Conversion Cycle (CCC) of RBC Bioscience is 122.73 in 2024.

Cash Conversion Cycle (CCC) of RBC Bioscience changed from 153.91 to 122.73, representing a -20.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — RBC Bioscience

All Key Metrics — RBC Bioscience